Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Genmab, Exercise of warrants - Capital Increase20 Aug 2003
Genmab, current statement of shareholdings11 Aug 2003
Genmab, interim report 20036 Aug 2003
Genmab, Announces 2003 First Half Year Results6 Aug 2003
Genmab, capital increase in Genmab A/S - directed offering25 Jul 2003
InvestorService: Genmab, Timing of Publication of Genmab’s Half-Year Results 200317 Jul 2003
Genmab, Expands Pipeline with Hepatitis Antibody14 Jul 2003
Genmab, Amgen Exercises Commercial Option to Genmab's HuMax-IL15
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
1 Jul 2003
Genmab, Genmab Files CTA for HuMax-EGFr to Treat Cancer27 Jun 2003
Genmab, Genmab's HuMax-CD20 Cancer Antibody Shows Promising Results in Primate Study26 Jun 2003
Genmab, Grant of Warrants in Genmab A/S25 Jun 2003
Genmab, quarterly statement of shareholdings18 Jun 2003
  • Previous
  • 1
  • More pages
  • 147
  • 148
  • 149
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863